Back to Search
Start Over
Metformin protects bone mass in ultra-high-molecular-weight polyethylene particle-induced osteolysis by regulating osteocyte secretion.
- Source :
-
Journal of Bone & Mineral Metabolism . May2019, Vol. 37 Issue 3, p399-410. 12p. - Publication Year :
- 2019
-
Abstract
- Metformin, an anti-hyperglycemic agent used for type 2 diabetes, has recently been found to have more effects apart from glucose regulation. We found that, in ultra-high-molecular-weight polyethylene particle-induced osteolysis mouse models, metformin had bone protect property and reduced the negative regulator of bone formation sclerostin (SOST) and Dickkopf-related protein 1 (DKK1), and increased osteoprotegerin (OPG) secretion and the ratio of OPG/Receptor Activator for Nuclear Factor-κB Ligand (RANKL). In vitro, we established a 3D co-culture system in which metformin affects osteoblasts and osteoclasts through mature osteocytes secretion. Metformin (50 μM) significantly decreased SOST and DKK1 mRNA expression, stimulating alkaline phosphatase activity and proliferation of osteoblast, and increased OPG secretion and the ratio of OPG/RANKL, inhibiting osteoclastogenesis. Moreover, the effect on OPG was reversed by adenosine 5'-monophosphate-activated protein kinase inhibitor, Compound C. Our finding suggests that metformin induces differentiation and mineralization of osteoblasts, while inhibits osteoclastogenesis via mature osteocytes secretion. Therefore, the drug might be beneficial for not only diabetes but also in other bone disorders by acting on mature osteocytes. [ABSTRACT FROM AUTHOR]
- Subjects :
- *OSTEOCYTES
*BONE resorption
*METFORMIN
*MOLECULAR weights
*POLYETHYLENE
Subjects
Details
- Language :
- English
- ISSN :
- 09148779
- Volume :
- 37
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Journal of Bone & Mineral Metabolism
- Publication Type :
- Academic Journal
- Accession number :
- 136187728
- Full Text :
- https://doi.org/10.1007/s00774-018-0939-7